Maverick Capital Ltd. Takes Position in Abbott Laboratories $ABT

Maverick Capital Ltd. purchased a new position in shares of Abbott Laboratories (NYSE:ABT) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,758,160 shares of the healthcare product maker’s stock, valued at approximately $180,510,000. Abbott Laboratories accounts for about 2.1% of Maverick Capital Ltd.’s investment portfolio, making the stock its 21st biggest position.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ABT. MidAtlantic Capital Management Inc. acquired a new stake in Abbott Laboratories in the fourth quarter worth $25,000. Cornerstone Financial Management LLC bought a new position in shares of Abbott Laboratories during the fourth quarter worth about $25,000. Purpose Unlimited Inc. acquired a new stake in shares of Abbott Laboratories in the 4th quarter worth about $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in Abbott Laboratories in the 4th quarter valued at about $26,000. Finally, Abound Financial LLC acquired a new position in Abbott Laboratories during the 4th quarter valued at about $26,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Stock Up 1.5%

ABT opened at $104.61 on Tuesday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The company has a market capitalization of $182.20 billion, a PE ratio of 33.85, a P/E/G ratio of 2.00 and a beta of 0.61. The stock’s fifty day moving average is $91.95 and its 200-day moving average is $100.99. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.65% and a net margin of 11.65%.The business had revenue of $12.51 billion during the quarter, compared to analysts’ expectations of $12.52 billion. During the same quarter last year, the business posted $1.26 earnings per share. The company’s quarterly revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities analysts predict that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s payout ratio is presently 81.55%.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on ABT shares. Leerink Partners dropped their price target on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research note on Tuesday, April 21st. Wells Fargo & Company increased their price objective on Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. Daiwa Securities Group lowered Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price target for the company. in a research report on Wednesday, April 22nd. Evercore lowered their price target on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Finally, Bank of America cut their price objective on shares of Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $118.61.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.